- Home
- PMVP vs IMAB Comparison
PMVP vs IMAB Comparison
Compare PMVP & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- IMAB
- Stock Information
- Founded
- PMVP 2013
- IMAB 2014
- Country
- PMVP United States
- IMAB United States
- Employees
- PMVP N/A
- IMAB N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- IMAB Health Care
- Exchange
- PMVP Nasdaq
- IMAB Nasdaq
- Market Cap
- PMVP 77.4M
- IMAB 384.6M
- IPO Year
- PMVP 2020
- IMAB 2020
- Fundamental
- Price
- PMVP $1.23
- IMAB $3.75
- Analyst Decision
- PMVP Strong Buy
- IMAB Strong Buy
- Analyst Count
- PMVP 1
- IMAB 5
- Target Price
- PMVP $5.00
- IMAB $6.80
- AVG Volume (30 Days)
- PMVP 2.6M
- IMAB 1.8M
- Earning Date
- PMVP 11-06-2025
- IMAB 11-02-2025
- Dividend Yield
- PMVP N/A
- IMAB N/A
- EPS Growth
- PMVP N/A
- IMAB N/A
- EPS
- PMVP N/A
- IMAB N/A
- Revenue
- PMVP N/A
- IMAB N/A
- Revenue This Year
- PMVP N/A
- IMAB N/A
- Revenue Next Year
- PMVP N/A
- IMAB N/A
- P/E Ratio
- PMVP N/A
- IMAB N/A
- Revenue Growth
- PMVP N/A
- IMAB N/A
- 52 Week Low
- PMVP $0.81
- IMAB $0.60
- 52 Week High
- PMVP $1.84
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- PMVP 42.03
- IMAB 45.97
- Support Level
- PMVP $1.19
- IMAB $3.20
- Resistance Level
- PMVP $1.40
- IMAB $4.64
- Average True Range (ATR)
- PMVP 0.16
- IMAB 0.42
- MACD
- PMVP -0.04
- IMAB -0.17
- Stochastic Oscillator
- PMVP 15.12
- IMAB 30.44
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).